Newer topical therapies for the treatment of acne vulgaris.
Newer topical therapies approved by the US Food and Drug Administration (FDA) for the treatment of acne vulgaris are dapsone gel 5% and clindamycin phosphate 1.2% and tretinoin 0.025% combination gel. Both are formulated in aqueous-based gel vehicles. These newer topical acne products have been shown to be effective and safe in pivotal 12-week phase 3 trials and long-term studies completed over 12 months. This article reviews applicable pharmacokinetic, efficacy, and safety data reported with both products.
Del Rosso
James Q
JQ
Valley Hospitatal Medical Center, Las Vegas, Nevada, USA.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology*; D003622:Dapsone / Q000494:pharmacology*; D004338:Drug Combinations; D006801:Humans; D007641:Keratolytic Agents / Q000494:pharmacology*; D016896:Treatment Outcome; D014212:Tretinoin / Q000494:pharmacology*
D000890:Anti-Infective Agents; D004338:Drug Combinations; D007641:Keratolytic Agents; D002981:Clindamycin; D014212:Tretinoin; D003622:Dapsone